EAN 2024 | What should be done in pregnancy for pts with myasthenia gravis & unanswered questions that remain

Jenny Lindroos, MD, PhD Candidate, University of Bergen, Bergen, Norway, highlights what should be done during pregnancy in patients with myasthenia gravis (MG) and emphasizes the safe use of intravenous immunoglobulin in these individuals. She also notes the limited understanding of antibody transfer into breast milk, particularly during the colostrum phase, and encourages further research in this area. This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.